

Risk of fracture with contemporary antiretrovirals within the RESPOND Consortium

Bastian Neesgaard¹, Win Min Han², Jennifer Hoy³, Angela Öllinger⁴, Huldrych Günthard^{5,6}, Josip Begovac⁷, Ferdinand Wit^{8,9}, Clara Lehmann¹⁰, Charlotte Martin¹¹, Andrew Carr¹², Cristina Mussini¹³, Antonella Castagna¹⁴, Fiona Burns¹⁵, Alex Schneider¹⁶, Martin Gisinger¹⁷, János Szlavik¹⁸, Philip Tarr¹⁹, Lauren Greenberg¹, Nadine Jaschinski¹, Jean van Wyk²⁰, Megan Dunbar²¹, Lital Young²², Kathy Petoumenos² and Lene Ryom^{1,23,24} *on behalf of RESPOND*

1: CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2: The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia; 3: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.; 4: Department of Dermatology and Venerology, Kepler University Hospital, Linz; 5: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; 6: Institute of Medical Virology, University of Zurich, Zurich, Switzerland; 7: University Hospital for Infectious Diseases, Zagreb, Croatia; 8: Amsterdam University Medical Center, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands; 9: Stichting HIV monitoring, Amsterdam, the Netherlands; 10: Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany; 11: Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium; 12: HIV and Immunology Unit, St Vincent’s Hospital, Sydney, ; 13: Modena HIV Cohort, Università Degli Studi di Modena, Modena, Italy; 14: San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy; 15: The Royal Free HIV Cohort Study, Royal Free Hospital, University College London, London, United Kingdom; 16: European AIDS Treatment Group (EATG); 17: Department of Dermatology, Venereology, and Allergy, Medical University Innsbruck, Innsbruck, Austria; 18: Department of Infectious Diseases, Central Hospital of Southern-Pest, National Institute of Haematology and Infectious Diseases, Budapest, Hungary; 19: University Center Internal Medicine and Infectious Diseases Service, Kantonsspital Baselland, University of Basel, Bruderholz, Switzerland; 20: ViiV Healthcare, London, United Kingdom; 21: Gilead Sciences, Foster City, California

Plain language summary

Whilst in our primary analyses, the use of integrase inhibitors and tenofovir alafenamide was associated with a small increase in fracture risk, this association was no longer evident after excluding the use of boosted protease inhibitors or tenofovir disoproxil fumarate, known to be associated with fractures, suggesting these findings are likely explained by treatment history and baseline risk.

- ### BACKGROUND

 - People with HIV have a higher fracture risk than those without HIV ¹⁻⁴
 - Tenofovir disoproxil fumarate (TDF) and boosted protease inhibitors (PI/b) have been linked to increased fracture risk ⁵⁻⁷
- The relationship between integrase strand transfer inhibitors (INSTIs) and/or tenofovir alafenamide (TAF) with fracture risk remains uncertain
- ### METHODS

 - We included RESPOND participants aged >18 years
 - Baseline: First visit after the later of local cohort enrolment or 1 January 2012. Follow-up (FU): until the latest of the final visit or 31 December 2022
 - Associations between established fracture risk factors and initiation of INSTI or TAF were assessed using logistic regression to evaluate potential confounding by indication
 - Poisson regression with generalised estimating equations and robust standard errors estimated adjusted relative risk for fractures with ever exposure to INSTIs and TAF
 - Sensitivity analyses excluded individuals with prior TDF and/or PI/b exposure and censored individuals who initiated either TDF or PI/b during follow-up


- ### RESULTS

 - A total of 40,244 participants were included (Table 1)
 - Participants who experienced a fracture were older, current smokers, and more likely to have a low BMI, chronic kidney disease, HCV, or a prior fracture
 - During a median follow-up of 8.4 years (301,862 person-years of follow-up), 2155 participants experienced one or more fractures (2,544 fractures in total)
 - Lower leg fractures were the most prevalent, accounting for 375 fractures (14.7%)

Table 1: Baseline demographics and clinical characteristics by fractures during FU				
	First Fracture after baseline		No Fracture	
	n	(%)	n	(%)
Total	2155	5.4	38089	94.6
Sex/gender				
Male	1604	74.4	28715	75.4
Ethnicity/race				
White	1718	79.7	27573	72.4
Black	135	6.3	4441	11.7
Geographical Region				
Western Europe	1227	56.9	17627	46.3
Southern Europe	250	11.6	6833	17.9
Northern Europe	555	25.8	8549	22.4
Eastern Europe	123	5.7	5080	13.3
HIV acquisition risk				
MSM	900	41.8	17995	47.2
IDU	398	18.5	4691	12.3
ART treatment history				
ART Experienced	1801	83.6	27475	72.1
ART Naïve	354	16.4	10614	27.9
Prior AIDS				
yes	615	28.5	7833	20.6
Smoking status				
Never	506	23.5	10573	27.8
Current	956	44.4	13311	34.9
BMI				
<18.5	103	4.8	1181	3.1
18.5-<25	932	43.2	15018	39.4
25-<30	144	6.7	2149	5.6
>30	475	22	7060	18.5
	103	4.8	1181	3.1
Co-morbidities				
HCV	592	27.5	7139	18.7
Hypertension	152	7.1	1411	3.7
Diabetes	1383	64.2	19871	6.1
Dyslipidaemia	190	8.8	2307	52.2
Prior fracture	96	4.5	806	2.1
Prior CVD	69	3.2	461	1.2
Continuous variables	Median	IQR	Median	IQR
Baseline CD4, cells/mm ³	515	351 - 705	513	338 - 709
Age, years	49	42 - 56	44	35 - 51
Percentage of overall unknowns: ethnicity: 15.9, Risk of HIV acquisition: 4.1, Prior AIDS: 5.4, BMI: 35.6, smoking status: 36.4, hypertension: 17.5, diabetes: 20.8, CKD: 9.8, and CVD: 9.8				
References: [1]: Shiao et al. <i>Aids</i> , 2013 [2]: Goh et al. <i>Osteoporosis International</i> , 2018 [3]: Bedimo et al. 2016 [4]: Hoy et al. <i>Journal of Bone and Mineral Research</i> , 2017 [5]: Alvarez-Barco et al. <i>Curr. Opin. HIV AIDS</i> , 2021 [6]: Bedimo et a. <i>Aids</i> , 2012 [7]: Borges et al. <i>Clinical Infectious Diseases</i> , 2017				

- ### RESULTS

 - There were 555 (21.8%) fractures at locations associated with osteoporosis (fractures of the spine, lower arm/wrist and hip)
 - Prior fractures were not associated with INSTI initiation but showed a small association with TAF initiation (OR 1.08; 95% CI 1.02–1.15).
 - Smoking status was significantly associated with INSTI and TAF initiation (1.26; 1.23-1.3 and 1.16; 1.12-1.20); eGFR <60 was borderline significant for both initiating INSTIs and TAF (1.05; 1.00-1.11 and 1.01; 0.95-1.07)
 - Age >40 years compared to older age groups was associated with a lower likelihood of initiating either an INSTI or TAF (global p <0.001 for both)
 - Ever exposure to INSTIs or to TAF was associated with a small increased relative fracture risk (Figure 1)
 - After excluding those with prior TDF use and censoring at TDF initiation, the associations were no longer statistically significant. Similar findings occurred when excluding prior PI/b exposure and censoring at PI/b initiation



- ### LIMITATIONS

 - Potential for confounding by indication, as seen, e.g., by prior fractures being associated with TAF initiation, and more smokers among those starting TAF and INSTI
 - Possible residual confounding by unmeasured factors or factors not collected, such as menopause status or use of corticosteroids.
 - A large number of fractures of unknown type and with unknown fracture location hampering differentiation of traumatic and osteoporotic fractures

- ### CONCLUSION

 - INSTI and TAF use were associated with a small increase in relative fracture risk in the primary analyses
 - The attenuation observed after accounting for TDF and PI/b exposure suggests the findings are likely due to confounding by treatment history and baseline risk factors, rather than reflecting a safety signal

Funding statement:
The CHU St Pierre Brussels HIV Cohort, The Austrian HIV Cohort Study, The Australian HIV Observational Database, The AIDS Therapy Evaluation in the Netherlands National Observational HIV cohort, The EuroSIDA cohort, The Frankfurt HIV Cohort Study, The Georgian National AIDS Health Information System, The Nice HIV Cohort, The ICONA Foundation, The Modena HIV Cohort, The PISCIS Cohort Study, The Swiss HIV Cohort Study, The Swedish InfCare HIV Cohort, The Royal Free HIV Cohort Study, The San Raffaele Scientific Institute, The University Hospital Bonn HIV Cohort and The University of Cologne HIV Cohorts, Merck Life Sciences, ViiV Healthcare, and Gilead Sciences.

RESPOND Study Group: <https://chip.dk/Research/Studies/RESPOND/Study-group>